Resources from the same session
85O - Low-pass whole genome sequencing (lpWGS) to quantify circulating tumor DNA (ctDNA) burden as a pharmacodynamic response biomarker in patients on early phase trials
Presenter: Aaron Tan
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
86O - Serial monitoring of circulating tumor DNA (ctDNA) as a tumor-agnostic biomarker to inform clinical outcomes of patients receiving experimental cancer medicine
Presenter: Kyrillus Shohdy
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
15O - Targeting CCNE1-amplified ovarian and endometrial cancers by combined inhibition of PKYMT1 and ATR
Presenter: Fiona Simpkins
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
1O - Uncovering new immunotherapy targets with machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Abstract session 2
Resources:
Abstract
74O - Highly potent and selective RET inhibitors that overcome adaptive drug resistance
Presenter: Li Xing
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
28O - Comparison of prognostic scores in oncology patients participating in phase I clinical trials with immunotherapy
Presenter: PALOMA Sangro
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
29O - Clinical characterization of long-term survivors in phase I clinical trials
Presenter: Oriol Mirallas
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
6O - Subcutaneous fat mass predicts progression-free survival in patients treated with antibody drug conjugates in early phase clinical trials
Presenter: Matthieu Delaye
Session: Abstract session 2
Resources:
Abstract
Q&A
Presenter: All Speakers
Session: Abstract session 2
Resources:
Webcast